In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ... Teva Pharmaceutical Industries Ltd. Price, Consensus and EPS Surprise ...

Teva Pharmaceutical Industries' Q4 2024 ... future shareholder-friendly activities like dividends or share repurchases. A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates ...

In February 2025, Teva Pharmaceuticals and Alvotech announced ... uncertainty regarding future sales performance and market share against established products like Stelara. The reliance on a ...

Teva Pharmaceutical Industries Ltd. (NYSE ... However, the company's share price opened nearly 10% lower on the NYSE due to a disappointing 2025 outlook. Teva has also provided guidance on ...

Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating estimates ... call that kicked off at 8 a.m. ET. TEVA Price Action: Teva Pharmaceutical shares were down 8.78% at ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full year 2024 financial results.